Neurocrine Biosciences Stock Current Valuation
| N1BI34 Stock | 36.16 0.49 1.37% |
Valuation analysis of Neurocrine Biosciences helps investors to measure Neurocrine Biosciences' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Neurocrine Biosciences' price fluctuation is very steady at this time. Calculation of the real value of Neurocrine Biosciences is based on 3 months time horizon. Increasing Neurocrine Biosciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Neurocrine Biosciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Neurocrine Stock. However, Neurocrine Biosciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 36.16 | Real 34.6 | Hype 36.16 | Naive 35.52 |
The real value of Neurocrine Stock, also known as its intrinsic value, is the underlying worth of Neurocrine Biosciences Company, which is reflected in its stock price. It is based on Neurocrine Biosciences' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Neurocrine Biosciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Neurocrine Biosciences helps investors to forecast how Neurocrine stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Neurocrine Biosciences more accurately as focusing exclusively on Neurocrine Biosciences' fundamentals will not take into account other important factors: Neurocrine Biosciences Company Current Valuation Analysis
Neurocrine Biosciences' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Neurocrine Biosciences Current Valuation | 58.19 B |
Most of Neurocrine Biosciences' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Neurocrine Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Neurocrine Biosciences has a Current Valuation of 58.19 B. This is much higher than that of the sector and significantly higher than that of the Drug Manufacturers-Specialty & Generic industry. The current valuation for all Brazil stocks is notably lower than that of the firm.
Neurocrine Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Neurocrine Biosciences' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Neurocrine Biosciences could also be used in its relative valuation, which is a method of valuing Neurocrine Biosciences by comparing valuation metrics of similar companies.Neurocrine Biosciences is currently under evaluation in current valuation category among its peers.
Neurocrine Fundamentals
| Return On Equity | 0.1 | |||
| Return On Asset | 0.0701 | |||
| Profit Margin | 0.10 % | |||
| Operating Margin | 0.17 % | |||
| Current Valuation | 58.19 B | |||
| Shares Outstanding | 1.93 B | |||
| Price To Book | 7.33 X | |||
| Price To Sales | 44.39 X | |||
| Revenue | 1.13 B | |||
| Gross Profit | 1 B | |||
| EBITDA | 138.1 M | |||
| Net Income | 89.6 M | |||
| Total Debt | 335.1 M | |||
| Book Value Per Share | 0.88 X | |||
| Cash Flow From Operations | 256.5 M | |||
| Earnings Per Share | 0.41 X | |||
| Number Of Employees | 1.2 K | |||
| Beta | 0.48 | |||
| Market Capitalization | 51.64 B | |||
| Total Asset | 2.07 B | |||
| Z Score | 92.4 | |||
| Net Asset | 2.07 B |
About Neurocrine Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Neurocrine Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neurocrine Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neurocrine Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Neurocrine Stock
When determining whether Neurocrine Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Neurocrine Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neurocrine Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neurocrine Biosciences Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurocrine Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Neurocrine Stock refer to our How to Trade Neurocrine Stock guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..